Concepedia

Rizwana Mohseni

RM

8

Publications

1.9K

Citations

8

H-Index

2019

Active since

Affiliations

Catalina Research Institute(Current)

Beth Israel Deaconess Medical Center

University of North Carolina at Chapel Hill

Texas Liver Institute

University of Pennsylvania

Rizwana Mohseni is an author at Catalina Research Institute specializing in obesity, metabolic syndrome, and medicine.

Top concepts

Publications per year

2019–2023

8

Publications

8

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 590 citations · Full text

, , +6

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Meagan P. O’Brien, Eduardo Forleo‐Neto, Bret J. Musser et al. · New England Journal of Medicine · 2021 · 470 citations · Full text

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

Samer Gawrieh, Mazen Noureddin, Nicole Loo et al. · Hepatology · 2021 · 335 citations · Full text

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas et al. · Gastroenterology · 2021 · 204 citations · Full text

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar et al. · Journal of Hepatology · 2023 · 163 citations · Full text

Rows per page

1–5 of 8